Astigmatism Market Poised for Robust Growth in the 7MM

Globe and Mail

14-04-2025

The Astigmatism companies in the market include - Johnson & Johnson, HOYA, Alcon, Lenstec Optical Group, HumanOptics, Carl Zeiss Meditec, Bausch + Lomb, Rayner, STAAR Surgical, EyeKon, Care Group, Morcher, Ophtec, Hanita Lenses, Omni Lens Pvt Ltd, Aurolab, SIFI, PhysIOL, and Excellent Hicare Pvt Ltd, and others.
The astigmatism market is witnessing significant growth in 7MM (United States, Canada, France, Germany, Italy, Spain, and the United Kingdom), driven by a combination of demographic trends, advancements in vision correction technologies, and an increasing awareness of eye health. Key companies, including Johnson & Johnson, HOYA, Alcon, Lenstec Optical Group, HumanOptics, Carl Zeiss Meditec, Bausch + Lomb, Rayner, STAAR Surgical, EyeKon, Care Group, Morcher, Ophtec, Hanita Lenses, Omni Lens Pvt Ltd, Aurolab, SIFI, PhysIOL, and Excellent Hicare Pvt Ltd, are leading innovation in this evolving landscape.
Develnsight's latest report, ' Astigmatism - Market Insight, Epidemiology And Market Forecast - 2032 ', combines robust epidemiological data with market trends, competitive landscape analysis, and assessments of the patient journey, providing valuable insights into the rapidly expanding astigmatism market.
Astigmatism is a common refractive error affecting a large global population, creating a substantial demand for corrective measures and vision enhancement technologies. The astigmatism market is projected to experience steady growth in the 7MM with a robust CAGR, driven by technological advancements in vision correction methods, rising awareness about eye health, and various demographic factors such as age and genetic predisposition. While the exact genetic mechanisms are not fully understood, several studies have indicated hereditary patterns whereby astigmatism often runs in families.
Download the Astigmatism market report to understand which factors are driving the Astigmatism treatment market @ Astigmatism Market Trends
The astigmatism epidemiology in the DelveInsight report reveals a significant burden. Astigmatism prevalence in the general population varied from 8 to 62%, with higher rates in individuals aged 70 years or older. Furthermore, the prevalence of with-the-rule astigmatism is more significant in individuals aged 40 years or younger, while rates of against-the-rule and oblique astigmatism tend to increase with age.
Gain valuable insights into the Astigmatism patient pool across the 7MM @ Astigmatism Epidemiology Analysis
The report also discusses current and emerging trends in astigmatism treatment. The current treatment landscape is diverse, offering both non-invasive and surgical options tailored to the severity of the condition and patient preferences.
Non-invasive treatments remain the most common approach to managing astigmatism. Prescription eyeglasses and contact lenses, particularly toric lenses, are widely utilized to correct the uneven curvature of the cornea, providing a simple and cost-effective solution for patients.
Refractive surgeries such as LASIK and PRK are highly effective options. Another surgical alternative involves implanting intraocular lenses during cataract surgery or refractive lens exchange. These lenses offer long-term vision correction and especially benefit older patients undergoing cataract surgery.
Orthokeratology presents a non-surgical alternative for correcting astigmatism, particularly in pediatric patients or those not yet ready for surgery, using specially designed rigid contact lenses overnight to temporarily reshape the cornea.
In January 2025, the MEL 90 excimer laser by Carl Zeiss Meditec AG received U.S. FDA approval for treating myopia, hyperopia, and mixed astigmatism, marking a significant milestone in refractive surgery. Equipped with the Triple-A ablation algorithm, the MEL 90 offers highly predictable, tissue-conserving procedures and can ablate 1 diopter in just 1.3 seconds during LASIK for myopia.
Emerging therapies are transforming the astigmatism treatment landscape by offering safer, minimally invasive, and highly effective alternatives to traditional surgical procedures. These innovations promise quicker recovery times and enhanced precision, addressing unmet needs in astigmatism management.
Notable developments include the introduction of toric intraocular lenses (IOLs) specifically designed to correct astigmatism during cataract surgery or refractive lens exchange. Another emerging alternative is SMILE (Small Incision Lenticule Extraction), a flapless procedure utilizing femtosecond laser technology, which is particularly suitable for patients with dry eyes or thin corneas.
Stay ahead with the latest breakthroughs, FDA approvals, and eco-friendly innovations shaping the future of the Astigmatism treatment landscape. Visit Astigmatism Recent Developments
As these emerging treatments gain traction, they address key unmet needs in astigmatism management, such as minimizing visual disturbances and expanding eligibility for procedures. With ongoing research and development in areas like gene-editing technologies, such as CRISPR/Cas9, and regenerative medicine, such as stem cell therapy to regenerate damaged ocular tissues, the future of the astigmatism treatment market looks increasingly promising.
Table of contents
1.
Key Insights
2.
Executive Summary of Astigmatism
3.
Astigmatism Competitive Intelligence Analysis
4.
Astigmatism: Market Overview at a Glance
5.
Astigmatism: Disease Background and Overview
6.
Patient Journey
7.
Astigmatism Epidemiology and Patient Population
8.
Treatment Algorithm, Current Treatment, and Medical Practices
9.
Astigmatism Unmet Needs
10.
Key Endpoints of Astigmatism Treatment
11.
Astigmatism Marketed Products
12.
Astigmatism Emerging Therapies
13.
Astigmatism: Seven Major Market Analysis
14.
Attribute analysis
15.
7MM: Market Outlook
16.
Access and Reimbursement Overview of Astigmatism
17.
KOL Views
18.
Astigmatism Market Drivers
19.
Astigmatism Market Barriers
20.
Appendix
21.
DelveInsight Capabilities
22.
Disclaimer
23.
About DelveInsight
Related Reports
Dry Age-Related Macular Degeneration Pipeline Insight
Dry Age-Related Macular Degeneration Pipeline Insight provides comprehensive insights about the Dry Age-Related Macular Degeneration pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Dry Age-Related Macular Degeneration manufacturers, including Belite Bio (NASDAQ: BLTE), Inflammx Therapeutics, Ocugen (NASDAQ: OCGN), OliX Pharmaceuticals, Gensight Biologics (NASDAQ: GNST), Alkeus Pharmaceuticals, Dobecure, Cognition Therapeutics (NASDAQ: CGTX), Aviceda Therapeutics, Galimedix Therapeutics, Mitotech (NASDAQ: MITO), Annexon, Inc. (NASDAQ: ANNX), NGM Biopharmaceuticals (NASDAQ: NGM), Johnson & Johnson, Lineage Cell Therapeutics, Astellas Pharma, Regenerative Patch Technologies, Hoffmann-La Roche, Boehringer Ingelheim, and ONL Therapeutics, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.